NEW YORK (GenomeWeb News) – Dyadic International has extended a collaboration with The Scripps Research Institute under which Scripps will re-annotate the genome of Dyadic's C1 fungus.
The company said that it has re-sequenced the C1 fungus that Scripps first annotated under a collaboration that began in 2006.
The results of that project and advances Dyadic has made have given the company the ability to develop new enzyme products and solutions and to develop the C1 platform, which it has licensed to Abengoa Bioenergy New Technologies and Codexis for use in enzyme and protein production.
The re-annotated genome "will provide Dyadic and its commercial partners with a more accurate blueprint of the C1 fungal strain," Dyadic's CEO Mark Emalfarb said in a statement.
"Our expertise in informatics, data analysis and software engineering, when combined with the C1 fungal genome should yield a powerful resource for understanding gene function, and development of important enzymes," Bruce Pascal, a principal investigator at Scripps Florida, added.
Financial terms of the agreement were not released.